Background-Atherosclerosis is a complex disease requiring improvements in diagnostic techniques and therapeutic treatments. Both improvements will be facilitated by greater exploration of the biology of atherosclerotic plaque. To this end, we carried out large-scale gene expression analysis of human atherosclerotic lesions. Methods and Results-Whole genome expression analysis of 101 plaques from patients with peripheral artery disease identified a robust gene signature (1514 genes) that is dominated by processes related to Toll-like receptor signaling, T-cell activation, cholesterol efflux, oxidative stress response, inflammatory cytokine production, vasoconstriction, and lysosomal activity. Further analysis of gene expression in microdissected carotid plaque samples revealed that this signature is differentially expressed in macrophage-rich and smooth muscle cell-containing regions. A quantitative PCR gene expression panel and inflammatory composite score were developed on the basis of the atherosclerotic plaque gene signature. When applied to serial sections of carotid plaque, the inflammatory composite score was observed to correlate with histological and morphological features related to plaque vulnerability. Conclusions-The robust mRNA expression signature identified in the present report is associated with pathological features of vulnerable atherosclerotic plaque and may be useful as a source of biomarkers and targets of novel antiatherosclerotic therapies. (Circ Cardiovasc Genet. 2011;4:595-604.)
of diagnostic techniques can accurately predict either plaque progression or response to treatment. Gene expression microarray technology and systems biology allow comprehensive characterization of the pathological processes associated with atherosclerosis, making possible the identification of new targets to treat this disease and new diagnostic measures of disease progression. 2 To understand the underlying disease pathophysiology and gain insights into plaque biology that could facilitate the discovery of new therapies, we have undertaken gene expression profiling of human plaque. Because of its availability and documented similarity to coronary plaque, 3, 4 we primarily studied peripheral plaque. The observations made in peripheral plaque were confirmed and extended in carotid plaque, also more available than coronary plaque but reported to share many features in common with both peripheral and coronary plaque. 3, 4 We report the identification of a gene expression signature allowing atherosclerotic plaque to be classified according to its relative inflamed or stable status. We also describe underlying biology of the signature and its association with clinically established markers of plaque instability.
Methods

Human Clinical Samples
The FoxHollow SilverHawk Catheter device (ev3, Inc, Plymouth, MN; www.ev3.net) was used to obtain peripheral plaque from the common femoral, superficial femoral, anterior tibial, peroneal, popliteal, posterior tibial, or tibial peroneal trunk arteries. Endarterectomy was used to obtain carotid plaque. 5 There were 5 independent plaque sets (Table) obtained and analyzed in this study. Set 1 contains 101 peripheral plaques obtained from 67 patients from extremities that were profiled in the Agilent platform. This set was used to identify the atherosclerotic plaque signature, to study the biological processes and pathways associated with it, and to study its correlation to the macrophage enriched module. Set 2 contains 1 carotid plaque that was serially sectioned and used for laser capture microscopy of plaque sections. Set 3 contains 6 carotid plaques that were embedded in optimal cutting temperature (OCT) medium and sliced in 226 sections (1 mm thick each). This set was used to correlate gene expression to the morphological characteristics of plaque. In this set, odd sections (113 sections) were used for gene expression profiling in the Affymetrix platform, and even sections (113 sections) were used for morphological evaluation of plaque. Set 4 contains 16 peripheral plaques from extremities profiled in the Agilent platform that was used to examine the performance properties of the quantitative (q)PCR panel.
Set 5 contains 8 carotid plaques. Their total mRNA was extracted, pooled together, and used as control reference pool for all plaques profiled in the 2-color Agilent platform.
Plaques from sets 1, 2, 4, and 5 were flash-frozen in liquid nitrogen. Plaques from set 3 were preserved in RNA later.
All patients provided written informed consent to participate. The study was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards.
Tissue Milling and Division
A complete description of sample processing by tissue milling and division has been submitted for publication (Reiser et al, Develop-ment and validation of a method for high-throughput simultaneous analysis of RNA, protein and lipid biomarkers in heterogeneous tissue specimens). Briefly, a plaque sample frozen in liquid nitrogen and a stainless steel bead were placed inside a TissueLyser (Qiagen) milling tube. The sample was milled at 30 Hz in 30-second intervals inside a liquid nitrogen bath to a fine, homogeneous powder. Samples were divided into 2 or 3 portions and stored at Ϫ80°C.
Plaque Slicing and Laser Capture Microscopy
Frozen, OCT-embedded plaque (10-m sections) from set 2 were prepared and mounted on Superfrost/Plus slides (Fisher Scientific). Slides were dehydrated with the HistoGene laser capture microscopy (LCM) Frozen Section Staining Kit (Molecular Devices). An immediately adjacent serial section was stained with anti-CD68 antibody (Novus) and used as guide to identify macrophage-rich and macrophage-poor areas. LCM was performed with Arcturus XT Microdissection System (Molecular Devices) using CapSure HS Caps (Molecular Devices). One macrophage-rich (intense CD68 staining) and 1 smooth muscle cell-rich (poor CD68 staining) section were isolated from 3 different plaque slices and used for gene expression profiling. RNA was extracted immediately after LCM with the PicoPure RNA Isolation Kit (Molecular Devices) and stored at Ϫ80°C.
RNA Isolation
Unless otherwise noted, total RNA was extracted by homogenization with a polytron in TRIzol (Invitrogen) and isolated using Wizard SV96 plates (Promega). RNA concentration was determined with RiboGreen (Invitrogen), and RNA integrity was evaluated on a 2100 Bioanalyzer (Agilent). Only plaques with RIN numbers greater than 8 and with 2 clear ribosomal RNA peaks (and therefore with nondegraded RNA) were used for further analysis.
Microarray Analysis
RNA and microarray processing were performed as described. 6 For plaques profiled in the Agilent platform (sets 1, 2, and 4), total RNA was amplified and labeled using a custom automated version of the MessageAmp II kit (Ambion). RNA was hybridized as described 6, 7 to custom Agilent microarrays (GEO accession No. GPL4372) containing 39 280 probes, using RNA from a pool of 8 human carotid plaques as control reference pool (set 5). To avoid bias from the Cy3 and Cy5 labels, fluoro-reverse duplicates were used for all samples (each sample is labeled independently with Cy3 and Cy5, mixed with labeled control pool RNA, and each reaction is independently hybridized to a single microarray, therefore using 2 arrays per sample). For plaques profiled in the Affymetrix platform (set 3), RNA was amplified and labeled using a custom automated version of the RT/IVT protocol and reagents provided by Affymetrix. RNA was hybridized to custom Affymetrix microarrays (GEO accession No. GPL10687) containing 37 582 probes.
Agilent data were processed using Rosetta Resolver error model, 8 and relative intensities were calculated for each gene in each plaque relative to the baseline represented by plaques in set 5. Affymetrix data were processed using robust multi-array average. 9 An initial assessment of data quality was performed as described in the microarray normalization methods section by Greenawalt and collaborators. 10 Each set (1-4) was processed independently. Before any biological analysis, gene expression patterns and their principal components of variation were checked against sample quality and process parameters to determine the effects of systematic biases resulting from technical variation within each plaque set. No significant biases were observed for any of the plaque sets studied, so the principal components analyzed in this study represented true biological signals. For set 3, 113 sections derived from 6 carotid plaques. Normalized mRNA expression in each section was directly correlated to the morphological features of that section, therefore it is not necessary to correct for patient bias. 
Data Analysis
Similarity searches were performed using Cosine correlation as distance metric. For each query gene (Ccl2, CD68, and 5-LO), an arbitrarily chosen number (100) of the most correlated and the same number of the most anticorrelated transcripts were identified (results were comparable when 200 or 300 transcripts were used instead, data not shown). These two sets of transcripts were used to split plaques in 2 major clusters by using hierarchical clustering with cosine distance metric. Transcripts differentially expressed between these 2 groups of plaques were identified by ANOVA, PϽ10e-8, which allowed the identification of a number of transcripts that facilitated downstream pathway analysis. Data were log transformed, follows normal distribution and the 2 groups of plaques classified by the seeds (Ccl2, CD68, and 5-LO) have equal variances as shown by using the Bartlett test. An estimation of false discovery rate for the plaque signature was obtained by repeating the entire process of signature identification 100 times with random seeds (instead of Ccl2, CD68, and 5-LO), and it is 12%. The false discovery rate estimated for LCM signature was calculated by permuting the labels 100 times, and it is 16%.
Two-dimensional unsupervised clustering analysis was performed by agglomerative function in Rosetta Resolver, which also uses cosine correlation as distance metric. Supervised clustering analysis was performed by Kmeans function and cosine correlation as distance metric.
Enrichment for biological processes was performed as described. 6 Briefly, the signature genes were compared with gene families in Gene Ontology, KEGG, Swissprot, and Panther databases. Probability values (Fisher exact test) were corrected for multiple testing (Bonferroni). Functional enrichment for disease classes was performed using DAVID software. 11 Pathway analysis was performed using Ingenuity Pathway Analysis (Ingenuity Systems) and Metacore (GeneGo) tools.
Quantitative PCR Analysis
TaqMan low-density array (Applied Biosystems) cards were custom configured into 96-gene sets. Each cDNA sample (100 L) was added to an equal volume of 2ϫ TaqMan Universal PCR Master Mix (Applied Biosystems) and amplified using an Applied Biosystems Prism 7900HT sequence detection system.
Results
An Atherosclerotic Plaque Gene Signature Can Segregate Plaque Samples
One hundred one atherosclerotic plaques from 67 patients with peripheral artery disease (set 1, Table; and online-only Data Supplement Table S1 ) were excised using the Silver-Hawk catheter, and RNA was extracted and hybridized to microarrays. Raw microarray data were deposited in the Gene Expression Omnibus (GEO) database (accession number GSE23314). As part of the initial quality control assessment, we determined that covariates such as sex, age, and medication did not influence any downstream analyses.
Because inflammation and extracellular matrix composition have been shown to affect plaque stability, [12] [13] [14] we investigated whether a set of genes, or atherosclerotic plaque "signature," related to inflammation and plaque stability could be identified among the transcripts differentially expressed in set 1 plaques ( Figure 1A ). To do this, we carried out an expression pattern similarity search (see Methods for details) using 3 well-characterized biomarkers of inflammation, Ccl2, 15 CD68, 16 and 5-lipoxygenase, 17 (5-LO) as queries. An arbitrarily chosen number (100) of the most correlated and the same number of the most anticorrelated transcripts were identified independently for each query gene Ccl2, CD68, and 5-LO (resulting in 3 sets of 200 transcripts). These 3 gene sets were then used independently to classify plaques in 2 groups: (1) plaques in which expression of the 100 genes correlated with the query gene was high and the expression of the 100 genes anticorrelated with these query gene was low and (2) plaques in which expression of the 100 genes correlated with the query gene was low and expression of the 100 genes most anticorrelated with the query gene was high (eg, Figure 1B ). The numbers of transcripts differentially expressed between each 2 groups of plaques were 2521 transcripts from the Ccl2 query, 2400 from CD68, and 3536 from 5-LO. The intersection of these 3 signatures consists of 1632 transcripts (online-only Data Supplement Table S2 ) corresponding to 1514 unique genes expressed in either a correlated or anticorrelated manner with the query genes (online-only Data Supplement Table S3 ).
A 2D hierarchical clustering of all the plaque samples using the 1632 transcript signature ( Figure 1C ) results in all plaques being placed in one of 3 groups: (1) plaques with high expression of Ccl2, CD68, 5-LO and genes with expression patterns correlated with these markers of inflammation, and low expression of stability markers (see below), the "inflamed" signature; (2) plaques with the "stable" signature, a gene expression pattern opposite to those with the "inflamed" signature, and (3) plaques with a mixed inflamed and stable expression pattern, the "intermediate" signature. A list of the transcripts comprising the inflamed signature (correlated with inflammation genes, 1108 transcripts) or the stability signature (anticorrelated with inflammation genes, 524 transcripts) in Figure 1C can be found in online-only Data Supplement  Table S2 .
Development of a Representative qPCR Panel
To confirm identification of expression signatures on an independent platform and to facilitate higher throughput analysis of plaque characteristics, we selected a panel of 79 genes for development of qPCR assays (online-only Data Supplement Table S4 ). Seventy-two genes were selected applying the following criteria: (1) robust (Ͼ2 fold) differential expression between plaques with inflamed and stable signatures, (2) high relative expression level, and (3) representation of key biological processes involved in plaque biology such as oxidative stress, cholesterol efflux, thrombosis, monocyte adhesion, shear stress, innate immunity, proteolysis, and so forth. Seven additional genes (ADAMDEC1, CCR2, EDNRA, JUB, MMP2, TXNIP, and XBP1) were added, based on reports from the literature. 18 -21 Analytic assay validation showed that gene expression measurements carried out on plaque samples with the qPCR panel were robust and reproducible (average R 2 ϭ0.92 for technical replicates and average CVϭ1.07% for assay-to-assay variability). Clustering analysis showed that the qPCR platform classifies plaque samples into inflamed and stable categories in the same manner as microarrays ( Figure 1C ). We observed good correlation between the 2 platforms at the level of individual genes when we compared gene expression measured by qPCR and microarray (Spearman Rϭ0.64 -0.96; online-only Data Supplement Table S5 ).
Enrichment and Pathway Analyses of the Atherosclerotic Plaque Signature Confirm Patterns of Inflammation and Stability
To correlate the atherosclerotic plaque signature with established histological and clinical characteristics of plaque, we determined what biological processes are associated with genes highly expressed in either the inflammation or stability gene sets (online-only Data Supplement Tables S6 and S7 , respectively). We found that lysosomal/vacuolar activities, inflammation/immune responses, and T-cell/leukocyte activation (online-only Data Supplement Table S6 ) were most highly associated with the inflammation gene set and muscle structure/development (online-only Data Supplement Table  S7 ) was most highly associated with the stability set.
We used pathway analysis to establish relationships among the genes upregulated in the plaque signature and confirm their biological relevance. We identified several signal transduction networks in the inflammation gene set, with central nodes at ERK, ErbB2, IL10, MAPK1, NF-B, PPAR-␥, and SREBF1. For example, we observed upregulation of key components of the NF-B signaling pathway in plaques with the inflamed signature, including NF-B activator RIPK2, 22 RIPK2 regulatory protein CARD14, 23 and TLR4 coreceptor for LPS LY96. 24 Pathway analysis tools also detected inflammation among the top biological processes and upregulation of antigen presentation by MHC class II and Toll-like receptor (TLR) pathways.
In addition, genes regulating several aspects of cholesterol metabolism are upregulated in plaques with the inflamed signature. These include scavenger receptors (such as SCARB1 and CD36), cholesterol efflux pumps (ABC-A1 and ABC-G1), apolipoproteins (ApoE), cholesterol transporters (NPC1 and NPC2), and other proteins involved in cholesterol metabolism (LCAT, LIPA, LPL, SOAT1, and CAV2) (online-only Data Supplement Table S3 ).
Intraplaque hemorrhage has been found associated with symptoms and rupture, 25 and expression of CD163, a scavenger receptor for hemoglobin-haptoglobin complexes, is expressed at higher levels in ruptured plaques. 26 In our peripheral plaque dataset, CD163 is significantly upregulated in plaques with inflamed signature (data not shown), and it is present in the atherosclerotic plaque signature (online-only Data Supplement Table S3 ). Gene families "muscle development" and "cytoskeleton" are upregulated in plaques with stable signature, including collagen genes (COL14A1, COL4A5, COL4A6), HEY2 and PRDM6, transcriptional repressors involved in smooth muscle cell proliferation, 27, 28 and other proteins involved in muscle development/contraction, such as integrin ␣-7 (ITGA7), phospholamban (PLN), sarcoglycan (SGCE), syntrophin alpha 1 (SNTA1), myosin light chain 9 (MYL9), and tropomyosin 1 (TPM1) (online-only Data Supplement Table S3 ).
The atherosclerotic plaque signature overlaps with the "disease mutation" gene family defined in SwissProt. This family of 1710 genes includes genes mutated in human disease (eg, NPC1) or having polymorphisms correlated with disease (eg, ApoE). Overlap between the disease mutation gene set and the atherosclerotic plaque signature is 148 genes (PϽ10 -7 , Fisher exact test; online-only Data Supplement  Table S8 ). Furthermore, functional enrichment for disease class association analysis in DAVID software showed enrichment for 5 disease classes (immune, infection, neurological, cardiovascular, and renal).
Macrophage-Enriched Module Components in the Inflamed Signature
Emilsson and collaborators identified a macrophage-enriched module (MEM) of Ϸ1600 genes conserved in mouse and humans whose expression is coregulated in liver and adipose. 29, 30 The MEM has a causal relationship with disease traits associated with metabolic syndrome, and it may play a role in macrophage infiltration of liver and adipose tissue. 29, 30 Because plaque formation and rupture are directly related to macrophage dysfunction, 31 we investigated whether the ath-erosclerotic plaque signature shares common features with the MEM. We found 422 genes overlapping between the plaque signature and the human MEM (PϽ10 Ϫ163 , Fisher exact test), including 5-LO, CD markers, cathepsins, matrix metalloproteinases, lysosomal enzymes, lysosomal transporters, cell cycle regulators, cytokines/chemokines, and chemokine receptors (online-only Data Supplement Table S9 ).
Atherosclerotic Plaque Signature Is a Measure of Plaque Cell Composition
High content of macrophages and foam cells, and loss of smooth muscle cells, could destabilize plaques and hence these cell types have been implicated as determinants of plaque stability. 32 To investigate if these 2 cell types provide the predominant features of the observed atherosclerotic plaque signature, we performed gene expression profiling of plaque regions enriched in macrophages or smooth muscle cells using LCM in a carotid plaque (set 2). RNA isolated from macrophage-rich and smooth muscle-rich regions dissected from 3 serial plaque sections (Figure 2A ) was subjected to microarray analysis. We identified 2934 differentially expressed genes (3118 transcripts) between regions of plaque rich in smooth muscle cells and macrophages (onlineonly Data Supplement Table S10 ). There was a significant overlap (PϽ10 Ϫ180 , Fisher exact test) between the inflammation signature in the atherosclerotic plaque signature and LCM macrophage signature but no significant overlap with LCM smooth muscle cell signature ( Figure 2B) . In contrast, the stable signature had a significant (PϽ10 Ϫ153 , Fisher exact test) overlap with LCM smooth muscle cell signature but no significant overlap with LCM macrophage signature ( Figure 2B ). 
Development of an Inflammation Composite Score
To standardize and simplify the quantitative analysis of gene expression, we developed an Inflammation Composite Score (ICS). The ICS for qPCR was defined as the difference between average expression values (expressed as 1/Ct, or inverse of cycle threshold) of all inflammation genes minus average expression values of all stability genes in the panel. Expression of all individual genes in the panel was normalized to total RNA. The ICS for microarray data were calculated as average expression values (expressed as ratios in logarithmic scale) of all inflammation genes minus the expression values of all stability genes from the whole plaque signature. Thus, both scores represent a quantitative readout of relative degree of inflammation in atherosclerotic plaque as determined by changes in gene expression. In the plaques we have studied, ICS values rank from Ϫ0.7 to 0.8, with a gaussian distribution centered at 0 (data not shown).
ICS for qPCR and microarrays are comparable for the same peripheral plaques (set 4) (data not shown). We calculated an ICS for the plaques in set 1, based on microarray data (Figure 3 ). Plaques that had been classified as "inflamed" by microarray-generated gene signature ( Figure 1C) had ICS values Ͼ Ͼ0, and plaques classified as "stable" by microarray signature ( Figure 1C) had ICS values Ͻ Ͻ0.
Inflammation Composite Score Is Linked to Markers of Plaque Vulnerability
To explore the relationship between gene expression and plaque morphology, we performed gene expression profiling and histological analyses in alternating sections (1 mm thick) across the length of 6 carotid plaques from endarterectomy procedures (see Methods, set 3).
We observed a correlation between gene expressionderived ICS values and histological features in plaque sections. Sections with characteristics of advanced inflamed plaque, high macrophage content, necrotic core, and thin fibrous cap showed higher ICS values. In contrast, sections from less advanced or more stable plaque with relatively high smooth muscle cell content showed lower ICS values (representative stained sections and ICS scores shown in Figure 4A and 4B). Regions rich in macrophages isolated by LCM have ICS Ͼ0, whereas regions rich in smooth muscle cells have ICS Ͻ0 ( Figure 4C ).
Discussion
Atherosclerosis is an inflammatory disease 31,33 associated with low-density lipoprotein (LDL) accumulation in the intima, activation of the endothelium, and recruitment of monocytes and T cells. The monocytes differentiate into macrophages, eventually becoming foam cells. These cells release cytokines, proteases, and vasoactive molecules, often intensifying inflammation to the point of local, extracellular proteolysis, and plaque rupture. To obtain a comprehensive view of the cellular processes involved in atherosclerotic plaque, we performed gene expression profiling of 101 human peripheral plaques. We identified an atherosclerotic plaque gene expression signature composed of 1514 genes that segregates plaques in 3 groups: those with high expression of genes correlated to CD68, Ccl2, and 5-LO and low expression of stability markers (plaques with inflamed signature), those with low expression of genes correlated to CD68, Ccl2, and 5-LO and high expression of stability markers (plaques with stable signature), and those with intermediate characteristics. The atherosclerotic plaque signature is robust and reproducible, as we demonstrated by the fact that it was well conserved among datasets obtained from studies several years apart and analyzed in 2 different platforms (Agilent and Affymetrix).
A limitation to our study results from the fact that in some cases multiple plaque samples were extracted from the same patient (we analyzed 101 plaques from 67 patients), and we were unable to match plaques with patients in the ANOVA model during identification of the plaque signature because that information was not available at the time of analysis. Thus, if all plaques from a single patient were identical, our analysis would be biased by multiple sampling of the same plaque. Analyses not reported in this study showed that when multiple plaques were obtained from the same patient, at different time points or from different locations (for example left versus right leg), each had a unique plaque signature. Overall, plaques from the same patient did not cluster together with regard to gene expression profile. This suggests that plaques from the same donor can be treated as independent samples.
The atherosclerotic plaque signature includes genes associated with inflammatory markers related to immune response and leukocyte activation, the TLR and MHC pathways, and the signaling cascade to NF-B. The TLRs and MHCs are part of the immune response system that responds to host infections. In the absence of pathogens, their activation in atherosclerosis may be a response to endogenous proinflammatory ligands such as oxidized LDL or excess lipids. 34 Increased expression of lymphocyte/macrophage markers is consistent with previous demonstrations that inflammation is a hallmark of peripheral plaques [35] [36] [37] and with the efficacy of treatments that reduce plaque inflammation. 38 Increased expression of CD163 is consistent with intraplaque hemorrhage.
We found a highly significant overlap between the atherosclerotic plaque signature and the MEM. 29, 30 The MEM contains a set of genes coregulated in mouse and human transcriptional networks involved in inflammatory response and macrophage activation pathways in brain, adipose, and liver tissues. 29, 30 The mouse MEM is enriched for genes that contribute to the risk of obesity, diabetes, and atherosclerosis-associated traits. 29 The human MEM has significant enrichment of genetic associations to clinical traits related to obesity. 30 Our observations suggest that genes in the MEM may be factors dictating human plaque characteristics and are consistent with previous observations involving macrophages in plaque formation. 31, 33 To our knowledge, this is the first time that the MEM has been associated with atherosclerosis in humans. Genes common to both the atherosclerotic plaque signature and the MEM have been proposed as potential contributors to plaque instability (eg, cathepsins 39 and matrix metalloproteinases 40 ) or plaque formation (sterol O-acyltransferase 41 ). However, there is no established link between atherosclerosis and the biological function of many other genes in this overlap. Thus, our results may help identify novel antiatherosclerotic therapeutic targets and quantifiable markers of atherosclerosis disease progression. We also identified significant enrichment in the atherosclerotic plaque signature for genes whose mutations cause, or are associated with, a variety of human diseases (ABCA1, GLA, GLB, LCAT, LPL, NPC1, and NPC2), further suggesting the presence of potential new pharmacological targets.
Plaques with inflamed signature express high levels of lysosomal genes. A strong lysosomal signal is consistent with the classical differentiation pattern of monocytes into macrophages, in which the activity of lysosomal enzymes such as acid phosphatase, ␤-glucuronidase and cathepsins and the number of lysosomes increase significantly as monocytes become macrophages. 42 The lysosome is the only organelle that can process the oxLDL through the activity of lysosomal acid lipase (LIPA). Formation of foam cells in atherosclerotic lesions is hypothesized to occur in part due to the accumulation of oxLDL in the lysosomes through progressive lysosomal dysfunction and loss of LIPA activity. 43 Lysosomal dysfunction and inflammation are parallel events because foam cell formation contributes to macrophage death, which in turn increases inflammation, 33, 44 attracting more monocytes that differentiate into macrophages, further increasing lysosomal gene expression.
We used LCM to perform high-resolution analysis of the cellular composition of human atherosclerotic plaque. We defined specific and robust gene expression signatures for the 2 primary plaque cell types, macrophages/foam cells and smooth muscle cells (SMC). Both macrophage and SMC content in plaque has been proposed to be associated with plaque vulnerability. 32, 45 When we compared the atherosclerotic plaque gene signature with cell type-specific signatures, we found significant overlaps between the inflamed gene set and a macrophage/foam cell signature and between the stable gene set and an SMC signature. This finding strongly suggests that whole plaque signatures reflect the distribution, molecular state, and dynamic behavior of macrophages and SMCs in plaque. We propose that the atherosclerotic plaque signature is directly related to changes in plaque composition, which in turn correlates with vulnerability.
The results from LCM experiments can provide a powerful method to develop gene expression patterns into cell typespecific information, improving interpretation of histological data. For example, the LCM approach identified gene expression signatures 50% larger than signatures obtained from whole tissue (Ϸ3000 transcripts versus Ϸ1600 transcripts). It is possible that more selective application of LCM, guided by histological probes that differentiate between related cell types, could yield more discrete signatures. These signatures could be compared with whole plaque signatures, possibly yielding a finer differentiation between plaque types.
To explore the translational potential of the atherosclerotic plaque signature, we selected a smaller panel of genes that we hypothesized could assess plaque composition and predict patient risk efficiently and quantitatively. We chose 79 genes with significant differential expression between plaques of high and low inflamed status (as defined by the profiling signatures) representing a variety of nonredundant pathological pathways (online-only Data Supplement Table S4 ). Like the microarray signature, the small qPCR panel had the ability to classify plaques into inflamed and stable categories. The qPCR panel is amenable to multiplexing and has a high degree of reproducibility, making it suitable for routine analysis in research or clinical laboratory setting.
To simplify and standardize quantification and interpretation of gene expression data measured by qPCR or microarray, we created a multi-analyte ICS. The ICS summarizes the gene expression level of the 79 genes into a single numeric value. We also defined an ICS for the entire microarray atherosclerotic plaque signature (containing 1514 genes) in an analogous manner and demonstrated that both scores perform comparably.
To assess the relevance of the inflamed and stability signatures identified in peripheral plaque to the biology of plaque from another anatomic location, we used the ICS to compare the gene signatures found in sections of carotid plaque with morphological and histological features of each section. Previous analyses of human atherosclerotic plaque from coronary and carotid arteries have suggested the importance of necrotic core size, inflammation level, and fibrous cap thickness as key determinants of plaque vulnerability. 46 A detailed, parallel histological and gene expression analysis of carotid plaque sections revealed that higher ICS values correlate with plaque regions that would be characterized as unstable: rich in macrophages, poor in smooth muscle cells, with thin fibrous cap and large necrotic core. In contrast, plaque sections with morphological features of less advanced or stable plaque have lower ICS values. This observation is entirely consistent with results from the LCM study demonstrating (1) a large overlap between macrophage and inflamed signatures and smooth muscle cells and stability signatures and (2) that higher ICS values are linked to plaque regions with increased macrophage content, whereas regions rich in smooth muscle cells have lower ICS. We note, however, that we did not carry out an exhaustive comparison of plaque histology and ICS score. Therefore, it remains possible that a relatively high ICS score could result from a low concentration of highly inflamed macrophages rather than be an absolute quantification of macrophage content. In either case, though, a high ICS score would signify an inflamed plaque or plaque section.
Overall, our results are consistent with previously published analyses of gene expression patterns in coronary plaque. 47, 48 Biological processes active in atherosclerotic plaque identified by King et al and in the present report include immune response, cell cycle, actin cytoskeleton, and muscle development (Tables 3 and 4 Supplement Tables  S6 and S7 ). Similarities between gene expression profiles in coronary and peripheral plaque are not surprising given the previously documented similarities in both morphology and cellularity between plaques from these different anatomic locations. 3, 4 Thus, it appears that the inflamed and stable signatures that we identified in peripheral plaque may be relevant to clinically important features of atherosclerotic plaque vulnerability in any anatomic site.
In summary, our results represent a comprehensive profiling analysis of human atherosclerotic plaque, including peripheral and carotid plaque samples, plaque sections, and subregions that identified a gene expression signature that classifies plaque into well-defined subtypes. Detailed analysis of carotid plaque sections showed that the atherosclerotic plaque signature is linked to plaque status and cellular composition. These markers of plaque status may be useful in the development of biomarkers for evaluation of patients as well as the discovery of new drugs to treat cardiovascular disease, particularly those that act through novel mechanisms. 49, 50 Finally, the datasets presented in the present study and deposited in the Gene Expression Omnibus (GEO) database (accession number GSE23314) represent a rich and unique resource to the biomedical research community.
